Trials / Terminated
TerminatedNCT00305019
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus
A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the antiviral effects and safety of clevudine 30 mg once a day (QD) and 50 mg QD in patients infected with hepatitis B virus (HBV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clevudine |
Timeline
- Start date
- 2002-07-01
- Completion
- 2004-03-01
- First posted
- 2006-03-21
- Last updated
- 2006-04-12
Locations
8 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00305019. Inclusion in this directory is not an endorsement.